{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T18:58:07Z","timestamp":1792868287035,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T00:00:00Z","timestamp":1558569600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T00:00:00Z","timestamp":1558569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40644-019-0208-6","type":"journal-article","created":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T15:06:52Z","timestamp":1558624012000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Optimizing prostate cancer accumulating model: combined PI-RADS v2 with prostate specific antigen and its derivative data"],"prefix":"10.1186","volume":"19","author":[{"given":"Yuan-Fei","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Gen","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong-Cong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0554-9484","authenticated-orcid":false,"given":"Ri-Sheng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,23]]},"reference":[{"issue":"4","key":"208_CR1","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","volume":"71","author":"N Mottet","year":"2017","unstructured":"Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate Cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71(4):618\u201329.","journal-title":"Eur Urol"},{"issue":"2","key":"208_CR2","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ajur.2016.08.010","volume":"4","author":"K Zhang","year":"2017","unstructured":"Zhang K, Bangma CH, Roobol MJ. Prostate cancer screening in Europe and Asia. Asian J Urol. 2017;4(2):86\u201395.","journal-title":"Asian J Urol"},{"issue":"1","key":"208_CR3","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1148\/radiol.2016161124","volume":"283","author":"AB Rosenkrantz","year":"2017","unstructured":"Rosenkrantz AB, Babb JS, Taneja SS, Ream JM. Proposed adjustments to PI-RADS version 2 decision rules: impact on prostate Cancer detection. Radiology. 2017;283(1):119\u201329.","journal-title":"Radiology."},{"key":"208_CR4","unstructured":"PI-RADS v2. https:\/\/www.acr.org\/-\/media\/ACR\/Files\/RADS\/Pi-RADS\/PIRADS-V2.pdf . Accessed 10 Jan 2019."},{"issue":"2","key":"208_CR5","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2214\/AJR.13.11046","volume":"202","author":"M de Rooij","year":"2014","unstructured":"de Rooij M, Hamoen EH, Futterer JJ, Barentsz JO, Rovers MM. Accuracy of multiparametric MRI for prostate cancer detection: a meta-analysis. AJR Am J Roentgenol. 2014;202(2):343\u201351.","journal-title":"AJR Am J Roentgenol"},{"issue":"11","key":"208_CR6","doi-asserted-by":"publisher","first-page":"762","DOI":"10.7326\/0003-4819-155-11-201112060-00375","volume":"155","author":"R Chou","year":"2011","unstructured":"Chou R, Croswell JM, Dana T, et al. Screening for prostate cancer: a review of the evidence for the U.S. preventive services task force. Ann Intern Med. 2011;155(11):762\u201371.","journal-title":"Ann Intern Med"},{"issue":"6","key":"208_CR7","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.acuro.2013.01.009","volume":"37","author":"C Hernandez","year":"2013","unstructured":"Hernandez C, Morote J, Minana B, Cozar JM. The role of prostate-specific antigen in light of new scientific evidence. Actas Urol Esp. 2013;37(6):324\u20139.","journal-title":"Actas Urol Esp"},{"issue":"5","key":"208_CR8","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1111\/bju.13619","volume":"119","author":"NL Hansen","year":"2017","unstructured":"Hansen NL, Barrett T, Koo B, et al. The influence of prostate-specific antigen density on positive and negative predictive values of multiparametric magnetic resonance imaging to detect Gleason score 7-10 prostate cancer in a repeat biopsy setting. BJU Int. 2017;119(5):724\u201330.","journal-title":"BJU Int"},{"issue":"5","key":"208_CR9","first-page":"448","volume":"85","author":"B Milkovic","year":"2014","unstructured":"Milkovic B, Dzamic Z, Pejcic T, et al. Evaluation of free-to-total prostate specific antigen (F\/T PSA), prostate specific antigen density (PSAD) and (F\/T)\/PSAD sensitivity on reduction of unnecessary prostate biopsies for patients with PSA in gray zone. Ann Ital Chir. 2014;85(5):448\u201353.","journal-title":"Ann Ital Chir"},{"issue":"2","key":"208_CR10","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/bju.13465","volume":"119","author":"S Washino","year":"2017","unstructured":"Washino S, Okochi T, Saito K, et al. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naive patients. BJU Int. 2017;119(2):225\u201333.","journal-title":"BJU Int"},{"issue":"1","key":"208_CR11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41391-017-0024-7","volume":"21","author":"Tobias Nordstr\u00f6m","year":"2017","unstructured":"Nordstrom T, Akre O, Aly M, Gronberg H, Eklund M. Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer. Prostate Cancer Prostatic Dis. 2018;21(1):57-63.","journal-title":"Prostate Cancer and Prostatic Diseases"},{"issue":"3","key":"208_CR12","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.juro.2012.10.009","volume":"189","author":"V Kasivisvanathan","year":"2013","unstructured":"Kasivisvanathan V, Dufour R, Moore CM, et al. Transperineal magnetic resonance image targeted prostate biopsy versus transperineal template prostate biopsy in the detection of clinically significant prostate cancer. J Urol. 2013;189(3):860\u20136.","journal-title":"J Urol"},{"issue":"1 Suppl","key":"208_CR13","first-page":"S2","volume":"189","author":"KL Greene","year":"2013","unstructured":"Greene KL, Albertsen PC, Babaian RJ, et al. Prostate specific antigen best practice statement: 2009 update. J Urol. 2013;189(1 Suppl):S2\u2013s11.","journal-title":"J Urol"},{"issue":"1","key":"208_CR14","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.juro.2009.08.139","volume":"183","author":"A Magheli","year":"2010","unstructured":"Magheli A, Hinz S, Hege C, et al. Prostate specific antigen density to predict prostate cancer upgrading in a contemporary radical prostatectomy series: a single center experience. J Urol. 2010;183(1):126\u201331.","journal-title":"J Urol"},{"issue":"2","key":"208_CR15","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.juro.2006.09.039","volume":"177","author":"SD Kundu","year":"2007","unstructured":"Kundu SD, Roehl KA, Yu X, Antenor JA, Suarez BK, Catalona WJ. Prostate specific antigen density correlates with features of prostate cancer aggressiveness. J Urol. 2007;177(2):505\u20139.","journal-title":"J Urol"},{"issue":"2","key":"208_CR16","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.eururo.2007.10.056","volume":"54","author":"P Finne","year":"2008","unstructured":"Finne P, Auvinen A, Maattanen L, et al. Diagnostic value of free prostate-specific antigen among men with a prostate-specific antigen level of <3.0 microg per liter. Eur Urol. 2008;54(2):362\u201370.","journal-title":"Eur Urol"},{"issue":"2s","key":"208_CR17","doi-asserted-by":"publisher","first-page":"S134","DOI":"10.1016\/j.juro.2016.10.099","volume":"197","author":"DF Gleason","year":"2017","unstructured":"Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 2017;197(2s):S134\u2013s139.","journal-title":"J Urol"},{"issue":"6","key":"208_CR18","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.eururo.2013.02.025","volume":"64","author":"A Bill-Axelson","year":"2013","unstructured":"Bill-Axelson A, Garmo H, Holmberg L, et al. Long-term distress after radical prostatectomy versus watchful waiting in prostate cancer: a longitudinal study from the Scandinavian prostate Cancer Group-4 randomized clinical trial. Eur Urol. 2013;64(6):920\u20138.","journal-title":"Eur Urol"},{"issue":"3","key":"208_CR19","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.eururo.2015.06.046","volume":"69","author":"JI Epstein","year":"2016","unstructured":"Epstein JI, Zelefsky MJ, Sjoberg DD, et al. A contemporary prostate Cancer grading system: a validated alternative to the Gleason score. Eur Urol. 2016;69(3):428\u201335.","journal-title":"Eur Urol"},{"issue":"11","key":"208_CR20","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/jama.280.11.969","volume":"280","author":"AV D'Amico","year":"1998","unstructured":"D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. Jama. 1998;280(11):969\u201374.","journal-title":"Jama."},{"issue":"5","key":"208_CR21","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.eururo.2012.01.050","volume":"61","author":"JI Epstein","year":"2012","unstructured":"Epstein JI, Feng Z, Trock BJ, Pierorazio PM. Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol. 2012;61(5):1019\u201324.","journal-title":"Eur Urol"},{"issue":"12","key":"208_CR22","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1159\/000441735","volume":"38","author":"R Knuchel","year":"2015","unstructured":"Knuchel R. Gleason score 6 - prostate Cancer or benign variant? Oncology research and treatment. 2015;38(12):629\u201332.","journal-title":"Oncology research and treatment"},{"issue":"1","key":"208_CR23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.eururo.2015.08.038","volume":"69","author":"JO Barentsz","year":"2016","unstructured":"Barentsz JO, Weinreb JC, Verma S, et al. Synopsis of the PI-RADS v2 guidelines for multiparametric prostate magnetic resonance imaging and recommendations for use. Eur Urol. 2016;69(1):41\u20139.","journal-title":"Eur Urol"},{"issue":"1083","key":"208_CR24","doi-asserted-by":"crossref","first-page":"20170645","DOI":"10.1259\/bjr.20170645","volume":"91","author":"M Brizmohun Appayya","year":"2018","unstructured":"Brizmohun Appayya M, Sidhu HS, Dikaios N, et al. Characterizing indeterminate (Likert-score 3\/5) peripheral zone prostate lesions with PSA density, PI-RADS scoring and qualitative descriptors on multiparametric MRI. Br J Radiol. 2018;91(1083):20170645.","journal-title":"Br J Radiol"},{"issue":"2","key":"208_CR25","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1148\/radiol.2018170425","volume":"288","author":"JN Thai","year":"2018","unstructured":"Thai JN, Narayanan HA, George AK, et al. Validation of PI-RADS version 2 in transition zone lesions for the detection of prostate Cancer. Radiology. 2018;288(2):485\u201391.","journal-title":"Radiology."},{"key":"208_CR26","doi-asserted-by":"crossref","unstructured":"Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery--what we have learned and where we are going. J Urol. 1999;162(2):293-306.","DOI":"10.1016\/S0022-5347(05)68543-6"},{"issue":"21","key":"208_CR27","first-page":"2528","volume":"120","author":"IA Eide","year":"2000","unstructured":"Eide IA, Angelsen A. Prostate-specific antigen. Tidsskrift for den Norske lageforening : tidsskrift for praktisk medicin, ny rakke. 2000;120(21):2528\u201331.","journal-title":"Tidsskrift for den Norske lageforening : tidsskrift for praktisk medicin, ny rakke"},{"issue":"4","key":"208_CR28","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.juro.2014.10.084","volume":"193","author":"NE Abraham","year":"2015","unstructured":"Abraham NE, Mendhiratta N, Taneja SS. Patterns of repeat prostate biopsy in contemporary clinical practice. J Urol. 2015;193(4):1178\u201384.","journal-title":"J Urol"},{"issue":"10071","key":"208_CR29","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","volume":"389","author":"HU Ahmed","year":"2017","unstructured":"Ahmed HU, El-Shater Bosaily A, Brown LC, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet (London, England). 2017;389(10071):815\u201322.","journal-title":"Lancet (London, England)"},{"issue":"2","key":"208_CR30","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0090-4295(00)00637-3","volume":"56","author":"WJ Catalona","year":"2000","unstructured":"Catalona WJ, Southwick PC, Slawin KM, et al. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology. 2000;56(2):255\u201360.","journal-title":"Urology."},{"key":"208_CR31","unstructured":"Filella X, Alcover J, Molina R, Carretero P, Ballesta AM. Clinical usefulness of PSA in the early diagnosis of prostate cancer. Vol 111998."},{"key":"208_CR32","unstructured":"Miele M. Percent free PSA as an additional measure in a prostate cancer screen. Vol 142001."},{"issue":"4","key":"208_CR33","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/bju.13836","volume":"120","author":"AR Alberts","year":"2017","unstructured":"Alberts AR, Roobol MJ, Drost FH, et al. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer. BJU Int. 2017;120(4):511\u20139.","journal-title":"BJU Int"},{"issue":"3","key":"208_CR34","doi-asserted-by":"publisher","first-page":"237","DOI":"10.5152\/tud.2017.01058","volume":"43","author":"M Scialpi","year":"2017","unstructured":"Scialpi M, Martorana E, Aisa MC, Rondoni V, D'Andrea A, Bianchi G. Score 3 prostate lesions: a gray zone for PI-RADS v2. Turk J Urol. 2017;43(3):237\u201340.","journal-title":"Turk J Urol"},{"issue":"2","key":"208_CR35","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1159\/000468947","volume":"99","author":"H Slaoui","year":"2017","unstructured":"Slaoui H, Neuzillet Y, Ghoneim T, et al. Gleason score within prostate abnormal areas defined by multiparametric magnetic resonance imaging did not vary according to the PIRADS score. Urol Int. 2017;99(2):156\u201361.","journal-title":"Urol Int"},{"issue":"1","key":"208_CR36","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/pros.20254","volume":"65","author":"C Savblom","year":"2005","unstructured":"Savblom C, Malm J, Giwercman A, Nilsson JA, Berglund G, Lilja H. Blood levels of free-PSA but not complex-PSA significantly correlates to prostate release of PSA in semen in young men, while blood levels of complex-PSA, but not free-PSA increase with age. Prostate. 2005;65(1):66\u201372.","journal-title":"Prostate"},{"issue":"1","key":"208_CR37","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/aja.2008.17","volume":"11","author":"ZY Liu","year":"2009","unstructured":"Liu ZY, Sun YH, Xu CL, Gao X, Zhang LM, Ren SC. Age-specific PSA reference ranges in Chinese men without prostate cancer. Asian journal of andrology. 2009;11(1):100\u20133.","journal-title":"Asian journal of andrology"}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-019-0208-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40644-019-0208-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-019-0208-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T14:23:42Z","timestamp":1721312622000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerimagingjournal.biomedcentral.com\/articles\/10.1186\/s40644-019-0208-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,23]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["208"],"URL":"https:\/\/doi.org\/10.1186\/s40644-019-0208-6","relation":{},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,23]]},"assertion":[{"value":"15 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The requirement for informed consent was waived by the institutional review board.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors have consented to the publication of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors who have taken part in this study have declared that they do not have any conflict of interest with respect to this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"26"}}